What this is
- How it works
- How it works isn't classified yet
- Tested for
- Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural, Mesothelioma Peritoneum, Cholangiocarcinoma, Cholangiocarcinoma Recurrent, Ovarian Cancer and 3 more
- Main trialPhase 1/2
- “Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate…”In the company’s words, NCT03907852 on ClinicalTrials.gov
Other drugs for Mesothelioma
- VT3989Vivace Therapeutics, Inc · Phase 3
- VolrustomigAstraZeneca · Phase 3
- EB-MF-CAR-NK-01Beijing Biotech · Phase 1/2
- PembrolizumabMerck & Co. · Phase 2
- VopimetostatTango Therapeutics, Inc. · Phase 1/2
- ISM6331InSilico Medicine Hong Kong Limited · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 19 Nov 2024 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026